| Antiviral Therapy for Patients With Liver Cancer After Surgery (NCT05466565) | Xiangya Hospital of Central South University | 2021-12-01 |
| PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer (NCT05103007) | Tongji Hospital | 2021-12-01 |
| Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma (NCT05166772) | Tianjin Medical University Cancer Institute and Hospital | 2021-12-01 |
| Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma (NCT05161143) | Peking Union Medical College Hospital | 2021-12-01 |
| Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform (NCT05242237) | The Second Affiliated Hospital of Chongqing Medical University | 2021-12-01 |
| Laparoscopic Versus Open Major Hepatectomy for HCC Hepatectomy for Hepatocellular Carcinoma (NCT04852211) | Chinese University of Hong Kong | 2021-12-01 |
| Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma (NCT05971199) | Zhejiang Cancer Hospital | 2021-11-23 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (NCT05024214) | 3D Medicines (Sichuan) Co., Ltd. | 2021-11-15 |
| Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma (NCT05148572) | National Cancer Centre, Singapore | 2021-11-10 |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection (NCT04981665) | Zhejiang University | 2021-11-08 |
| SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma (NCT05093608) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-03 |
| Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC (NCT05420922) | Tongji Hospital | 2021-11-01 |
| Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (NCT05072041) | Next Biomedical Co., Ltd. | 2021-10-31 |
| DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab (NCT04954339) | Tae Won Kim | 2021-10-29 |
| Multimodal Ultrasound and Hepatocellular Response to Local Treatments (NCT05987514) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-10-07 |
| Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma (NCT05048017) | Peking Union Medical College Hospital | 2021-10-01 |
| Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC (NCT05068076) | Institute of Liver and Biliary Sciences, India | 2021-10-01 |
| Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma (NCT05053386) | Zhejiang Cancer Hospital | 2021-10-01 |
| A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients (NCT05281926) | National Taiwan University Hospital | 2021-10-01 |
| SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma (NCT04930315) | Zhejiang University | 2021-09-15 |
| Low Dose ICG for Biliary Tract and Tumor Imaging (NCT04942665) | University of Florida | 2021-09-15 |
| GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma (NCT05047510) | Chinese Academy of Sciences | 2021-09-10 |
| Hepatocellular Carcinoma Imaging Using PSMA PET/CT (NCT05095519) | Peter MacCallum Cancer Centre, Australia | 2021-09-08 |
| A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers (NCT05068193) | Boryung Pharmaceutical Co., Ltd | 2021-09-06 |
| Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma (NCT04724226) | Sun Yat-sen University | 2021-09-01 |
| Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients (NCT04802954) | IHU Strasbourg | 2021-09-01 |
| The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma (NCT05088811) | Alexandria University | 2021-08-21 |
| Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma (NCT05010434) | Sun Yat-sen University | 2021-08-16 |
| Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma (NCT05003700) | Nanfang Hospital, Southern Medical University | 2021-08-12 |
| Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217) | ImmVira Pharma Co. Ltd | 2021-08-10 |
| GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma (NCT05178043) | Suzhou Kintor Pharmaceutical Inc, | 2021-08-01 |
| Contrast Enhanced Ultrasound (CEUS) in Atypical Liver Nodules in Patients With Chronic Liver Disease (NCT05772403) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-08-01 |
| Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer (NCT04745390) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2021-08-01 |
| Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC (NCT05056337) | Shanghai Zhongshan Hospital | 2021-08-01 |
| Fusion Imaging Contrast-enhanced Ultrasound LI-RADS (NCT04955119) | Tianjin Third Central Hospital | 2021-07-30 |
| Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma (NCT04798781) | Andrew Hendifar, MD | 2021-07-28 |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (NCT04145141) | National Cancer Institute (NCI) | 2021-07-28 |
| SBRT With DIBH for HCC After TACE and Lipiodol Marking (NCT05021250) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-07-21 |
| TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) (NCT04954794) | Fudan University | 2021-07-14 |
| The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC) (NCT04961918) | Sun Yat-sen University | 2021-07-13 |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma (NCT04803994) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2021-07-06 |
| The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) (NCT04517227) | Fudan University | 2021-07-01 |
| Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study (NCT04975932) | Zhongda Hospital | 2021-07-01 |
| Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy (NCT04994236) | Hui-Chuan Sun | 2021-07-01 |
| PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC (NCT04792801) | University Hospital, Lille | 2021-06-22 |
| Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma (NCT05024539) | Shujun Yang | 2021-06-20 |
| SBRT + Atezolizumab + Bevacizumab in Resectable HCC (NCT04857684) | Massachusetts General Hospital | 2021-06-18 |
| Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC (NCT04943679) | Shanghai Zhongshan Hospital | 2021-06-15 |
| An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) (NCT04563338) | University Health Network, Toronto | 2021-06-04 |
| The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK) (NCT04573881) | HistoSonics, Inc. | 2021-06-04 |
| Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma (NCT03908255) | Louisiana State University Health Sciences Center in New Orleans | 2021-06-01 |
| Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma (NCT05178524) | Tongji Hospital | 2021-06-01 |
| Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC (NCT05062837) | Guangxi Medical University | 2021-06-01 |
| Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) (NCT04658147) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-05-28 |
| Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma (NCT04791735) | Assistance Publique - Hôpitaux de Paris | 2021-05-21 |
| Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study (NCT04550481) | Northwestern University | 2021-05-11 |
| HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC (NCT05029973) | Tianjin Medical University Cancer Institute and Hospital | 2021-05-10 |
| Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） (NCT04806243) | Nanfang Hospital, Southern Medical University | 2021-05-06 |
| cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria (NCT04842565) | Fudan University | 2021-05-01 |
| Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC (NCT04843943) | Fudan University | 2021-05-01 |
| PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial (NCT04814043) | Sun Yat-sen University | 2021-04-20 |
| Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (NCT04814030) | Sun Yat-sen University | 2021-04-20 |
| Personalized Cancer Vaccine in Egyptian Cancer Patients (NCT05059821) | zeinab ahmed yousif hasan ashour | 2021-04-19 |
| A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients (NCT06518434) | University Medical Center Groningen | 2021-04-15 |
| Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC (NCT04912765) | National Cancer Centre, Singapore | 2021-04-15 |
| Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC (NCT05339321) | Peking Union Medical College Hospital | 2021-04-14 |
| Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (NCT04502082) | Eureka Therapeutics Inc. | 2021-04-14 |
| The Effect of Ultrasound-guided Erector Spinae Plane Block on Postoperative Analgesia in Radiofrequency Ablation Therapy (NCT04837742) | National Taiwan University Hospital | 2021-04-14 |
| Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (NCT04791176) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-04-12 |
| Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring (NCT06005883) | Keimyung University Dongsan Medical Center | 2021-04-10 |
| PAtient-PHYsician Relationship Assessment (NCT05729230) | Erasme University Hospital | 2021-04-05 |
| Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma (NCT04526080) | Wake Forest University Health Sciences | 2021-04-01 |
| Volatile Organic Compounds for the Assessment of Liver Disease (NCT04620538) | Imperial College London | 2021-04-01 |
| Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis (NCT04763707) | Sohag University | 2021-04-01 |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (NCT04521153) | Shanghai Zhongshan Hospital | 2021-03-25 |
| Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma (NCT05411926) | Beijing Tsinghua Chang Gung Hospital | 2021-03-17 |
| A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma (NCT05099848) | Shandong Cancer Hospital and Institute | 2021-03-17 |
| Deep Liver Phenotyping and Immunology Study (NCT04946773) | University of Oxford | 2021-03-12 |
| A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma (NCT04712643) | Hoffmann-La Roche | 2021-03-12 |
| Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (NCT03937830) | National Cancer Institute (NCI) | 2021-03-10 |
| The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin Resistance (NCT04649671) | Samsung Medical Center | 2021-03-02 |
| Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma (NCT06199297) | Sun Yat-sen University | 2021-03-02 |
| A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer (NCT05371873) | First Affiliated Hospital of Zhejiang University | 2021-03-01 |
| Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors (NCT04952272) | Second Affiliated Hospital of Guangzhou Medical University | 2021-03-01 |
| NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors (NCT05131763) | Fudan University | 2021-03-01 |
| Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy (NCT04676633) | Sirnaomics | 2021-03-01 |
| 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer (NCT04762888) | Mayo Clinic | 2021-02-24 |
| Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (NCT04727307) | University Hospital, Montpellier | 2021-02-23 |
| Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA) (NCT04777942) | Sun Yat-sen University | 2021-02-20 |
| Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors (NCT04315883) | Nemours Children's Clinic | 2021-02-11 |
| A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC (NCT04720716) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-02-07 |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (NCT04567615) | Bristol-Myers Squibb | 2021-02-04 |
| A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). (NCT04826406) | Hunan Cancer Hospital | 2021-02-03 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors (NCT04696055) | Bayer | 2021-02-03 |
| Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC (NCT02650271) | Guangxi Medical University | 2021-02-02 |
| DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma (NCT04229355) | Guangxi Medical University | 2021-02-02 |
| Nurse-led Decision Counseling on Hepatocellular Carcinoma Screening (NCT04659005) | Chinese University of Hong Kong | 2021-02-01 |
| Relevance of Sarcopenia in Advanced Liver Disease (NCT05502198) | Linkoeping University | 2021-02-01 |
| TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites (NCT04640116) | Sun Yat-sen University | 2021-02-01 |